Litcius/Paper detail

1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

M.P. Ducreux, R. Desgrippes, Y. Rinaldi, F. Di Fiore, R. Guimbaud, P. Follana, Jean‐Baptiste Bachet, P. Vanelslander, T. Lecomte, O. Capitain, A. Parzy, M. Bolliet, P-L. Etienne, J. Forestier, F. El Hajbi, A.L. Bignon Bretagne, V. Ly Lebrun, N. De Sousa Carvalho, M. Texier, O. Bouche

2022Annals of Oncology15 citationsDOIOpen Access PDF

Topics & Concepts

MedicineFOLFIRINOXGemcitabineClinical endpointInternal medicineHazard ratioPopulationPancreatic cancerSurgeryGastroenterologyOncologyCancerConfidence intervalRandomized controlled trialOxaliplatinColorectal cancerEnvironmental healthPancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCancer Diagnosis and Treatment
1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC) | Litcius